Table 2b.

Meta-regression analysis for overall survival.

Delta OS						OS hazard ratio
Variable	Beta coefficient	N studies	p value	SE	95 % CI	Beta coefficient	N studies	p value	SE	95 % CI
Final year of accrual	−0.19	9	0.62	60.99	−144.41 to 144.003	0.71	8	0.05	5.12	−11.82 to 13.24
Duration of bisphosphonates	0.46	9	0.21	55.27	−130.23 to 131.15	−0.06	8	0.88	7.25	−17.80 to 17.68
Median age	0.13	7	0.78	55.32	−142.07 to 142.33	0.40	6	0.43	7.12	−19.37 to 20.17
Post-menopausal	−0.18	9	0.64	61.13	−144.73 to 144.37	0.38	8	0.35	6.72	−16.06 to 16.82
pNode+	−0.13	9	0.74	72.42	−171.38 to 171.12	0.57	9	0.14	5.34	−12.06 to 13.20
>=pT3	0.05	6	0.93	59.36	−164.76 to 164.86	0.32	5	0.6	6.27	−19.63 to 20.27
HR negative	−0.27	7	0.56	70.23	−180.80 to 180.26	0.58	7	0.17	5.93	−14.66 to 15.82
Grade 2	−0.51	6	0.31	53.66	−149.49 to 148.47	0.98	5	0.003	1.25	−3.00 to 4.96
Grade 3	−0.49	7	0.26	51.42	−132.67 to 131.69	0.5	6	0.31	7.04	−19.05 to 20.05
Received NACT/ACT	−0.24	9	0.54	60.37	−142.99 to 142.51	0.73	8	0.04	5.00	−11.50 to 12.96
Taxane%	−0.83	6	0.037	42.98	−120.16 to 118.50	0.76	6	0.08	3.73	−9.60 to 11.12
Anthracycline%	−0.27	6	0.60	76.01	−211.31 to 210.77	0.46	6	0.36	5.10	−13.70 to 14.62

SE−standard error, CI- confidence interval, HR = hormone receptor, NACT = neoadjuvant chemotherapy. ACT = Adjuvant chemotherapy, DFS = disease free survival.